Neutral
Analysts from Barclays and KeyBanc have issued bullish ratings for Merck & Company (MRK) and Resmed (RMD), respectively. Barclays analyst Emily Field ...
ResMed (RMD) has experienced a recent stock pullback with declines over the past day, month, and three months, despite earlier five-year gains. With a...
Neutral
ResMed (NYSE:RMD) recently hit a new 52-week low, trading at $215.30 before closing at $217.2260. Despite this, analysts maintain a "Moderate Buy" con...
Neutral
Fifteen brokerages have issued a "Moderate Buy" consensus recommendation for ResMed Inc. (NYSE:RMD), with an average 12-month price target of $294.55....
Neutral
Certuity LLC significantly increased its stake in ResMed Inc. (NYSE:RMD) by 561.7% in the fourth quarter, now holding 6,736 shares valued at $1.62 mil...
Bullish
Google's 2026 Discover Core Update is changing how retail investors access information on ResMed Inc. (US7611521078) stock. The update delivers tailor...
Neutral
ResMed Inc. stock has fallen to a 52-week low of $218.20, significantly down from its high, reflecting a 7.55% decline over the past year and a 16% dr...
Bullish
ResMed Inc. leads the sleep apnea treatment market with innovative devices and a strong "razor-and-blade" business model, supported by growing awarene...
Bullish
ResMed Inc. leads the sleep health solutions market with its CPAP machines and masks, supported by recurring revenue from consumables and integrated s...
Bullish
ResMed Inc. is a leading medical device company focusing on sleep-disordered breathing and respiratory care, positioned for growth due to rising deman...
Bullish
This article compiles various trade ideas and technical analyses for ResMed Inc. (LSX:935168, NYSE:RMD) from different traders on TradingView. The ana...